Axsome Therapeutics IncNASDAQ:AXSM
- LAST PRICE98.4900
- TODAY'S CHANGE (%)-1.1600 (-1.1641%)
- Bid / Lots98.3700/ 6
- Ask / Lots98.6100/ 1
- Open / Previous Close100.0000 / 99.6500
- Day Range
- 52 Week Range
- Volume144,658
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AXSM |
|---|---|---|
| 09:32 ET | 2702 | 100 |
| 09:35 ET | 600 | 99.895 |
| 09:42 ET | 3100 | 99.65 |
| 09:44 ET | 4240 | 99.97 |
| 09:46 ET | 485 | 100.24 |
| 09:48 ET | 1146 | 100.005 |
| 09:50 ET | 2704 | 100.42 |
| 09:51 ET | 11261 | 100.025 |
| 09:53 ET | 2829 | 99.31 |
| 09:55 ET | 650 | 99.44 |
| 09:57 ET | 2350 | 98.995 |
| 10:00 ET | 1840 | 99.3 |
| 10:02 ET | 2800 | 99.04 |
| 10:04 ET | 325 | 99.19 |
| 10:06 ET | 1502 | 99.56 |
| 10:08 ET | 1500 | 99.775 |
| 10:09 ET | 4855 | 99.38 |
| 10:11 ET | 400 | 99.21 |
| 10:13 ET | 1635 | 99.3 |
| 10:15 ET | 504 | 99.46 |
| 10:20 ET | 2908 | 99.13 |
| 10:22 ET | 700 | 99.235 |
| 10:26 ET | 1292 | 98.9801 |
| 10:27 ET | 408 | 98.82 |
| 10:29 ET | 364 | 98.8 |
| 10:33 ET | 1000 | 98.78 |
| 10:36 ET | 300 | 98.85 |
| 10:38 ET | 700 | 98.78 |
| 10:40 ET | 1300 | 98.98 |
| 10:44 ET | 5173 | 98.835 |
| 10:45 ET | 4429 | 98.825 |
| 10:47 ET | 379 | 98.7081 |
| 10:49 ET | 100 | 98.82 |
| 10:51 ET | 1513 | 98.98 |
| 10:54 ET | 700 | 98.99 |
| 10:56 ET | 1020 | 99.08 |
| 10:58 ET | 700 | 99 |
| 11:00 ET | 4260 | 98.85 |
| 11:02 ET | 290 | 98.845 |
| 11:03 ET | 600 | 98.66 |
| 11:05 ET | 339 | 98.5439 |
| 11:07 ET | 1950 | 98.385 |
| 11:09 ET | 537 | 98.44 |
| 11:12 ET | 1934 | 98.89 |
| 11:14 ET | 900 | 98.45 |
| 11:16 ET | 3100 | 98.47 |
| 11:18 ET | 300 | 98.29 |
| 11:20 ET | 100 | 98.25 |
| 11:21 ET | 1417 | 98.3 |
| 11:23 ET | 100 | 98.42 |
| 11:25 ET | 300 | 98.595 |
| 11:27 ET | 200 | 98.51 |
| 11:30 ET | 100 | 98.64 |
| 11:32 ET | 2807 | 98.5 |
| 11:34 ET | 396 | 98.4357 |
| 11:36 ET | 750 | 98.46 |
| 11:38 ET | 800 | 98.4 |
| 11:39 ET | 500 | 98.34 |
| 11:41 ET | 200 | 98.3 |
| 11:43 ET | 300 | 98.48 |
| 11:45 ET | 532 | 98.495 |
| 11:48 ET | 511 | 98.49 |
Nov 27, 2024
DJ Axsome Therapeutics Price Target Maintained With a $180.00/Share by HC Wainwright & Co., from 6:44AM ET on Wednesday Nov 27, 2024 by Dow Jones
6:44AM ET on Wednesday Nov 27, 2024 by Dow Jones
Nov 26, 2024
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy, from 7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
Nov 25, 2024
DJ Axsome Therapeutics Price Target Maintained With a $180.00/Share by HC Wainwright & Co., from 8:29AM ET on Monday Nov 25, 2024 by Dow Jones
8:29AM ET on Monday Nov 25, 2024 by Dow Jones
Nov 13, 2024
DJ Axsome Therapeutics Is Maintained at Outperform by Baird, from 7:28AM ET on Wednesday Nov 13, 2024 by Dow Jones
7:28AM ET on Wednesday Nov 13, 2024 by Dow JonesDJ Axsome Therapeutics Price Target Maintained With a $130.00/Share by Needham, from 5:29AM ET on Wednesday Nov 13, 2024 by Dow Jones
5:29AM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Axsome Therapeutics Inc | 4.8B | -15.1x | --- |
ADMA Biologics Inc | 5.2B | 72.5x | --- |
TG Therapeutics Inc | 5.4B | -330.7x | --- |
Arcellx Inc | 4.9B | -122.7x | --- |
CRISPR Therapeutics AG | 4.3B | -18.3x | --- |
Blueprint Medicines Corp | 6.0B | -45.9x | --- |
Company Information
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Contact Information
- Headquarters
- One World Trade Center, 22Nd FloorNEW YORK, NY, United States 10007
- Phone
- 212-332-3241
- Fax
- 212-320-0245
Executives
- Chairman of the Board, President, Chief Executive Officer, Founder
- Herriot Tabuteau
- Chief Financial Officer
- Nick Pizzie
- Chief Operating Officer
- Mark Jacobson
- Executive Vice President - Product Strategy
- Lori Englebert
- Executive Vice President - Head of Commercial
- Ari Maizel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.8B |
|---|---|
Revenue (TTM) | $338.5M |
Shares Outstanding | 48.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.18 |
EPS | $-6.54 |
Book Value | $4.03 |
P/E Ratio | -15.1x |
Price/Sales (TTM) | 14.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -90.48% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
